Clinical Trials Logo

Luminal B clinical trials

View clinical trials related to Luminal B.

Filter by:
  • None
  • Page 1

NCT ID: NCT03875573 Active, not recruiting - Luminal B Clinical Trials

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:

Neo-CheckRay
Start date: November 6, 2019
Phase: Phase 2
Study type: Interventional

Neo-CheckRay is a multicenter, open-label phase II study that randomizes luminal B breast cancer subjects candidate for neo-adjuvant chemotherapy in a 1:1:1 ratio in 3 arms: 1. the combination of weekly paclitaxel followed by dose-dense doxorubicin-cyclophosphamide (ddAC) and pre-operative radiation therapy (boost dose) on the primary tumour 2. arm 1 with the addition of the anti-PD-L1 antibody durvalumab 3. arm 2 with the addition of the anti-CD73 antibody oleclumab The primary tumour will be excised 2-6 weeks after completion of ddAC. A safety run-in is planned for the 6 first subjects before starting the randomized phase II trial. Those 6 subjects will receive the treatment given in Arm 3.

NCT ID: NCT03860740 Completed - Breast Cancer Clinical Trials

Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients

EFIK
Start date: June 2016
Phase:
Study type: Observational

Observational study to evaluate the effect of physical exercise prior to surgery and adjuvant systemic treatment in women with newly diagnosed operable hormone receptor(HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers

NCT ID: NCT03356860 Completed - Breast Cancer Clinical Trials

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

B-IMMUNE
Start date: April 13, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The study has a phase Ib and a phase II part. - The phase Ib aims to evaluate the safety and tolerability of durvalumab in combination with a dose- dense EC regimen in a neoadjuvant setting for early breast cancer. - The phase II aims to explore the efficacy of durvalumab in combination with a dose-dense EC regimen in a neoadjuvant setting for early breast cancer.